Navigation Links
Neurological protein may hold the key to new treatments for depression
Date:11/29/2010

For Immediate Release November 29, 2010 (Toronto) Neuroscientists at the Centre for Addiction and Mental Health (CAMH) have developed a protein peptide that may be a novel type of highly targeted treatment for depression with a low side-effect profile. Depression affects one in ten Canadians at some time in their lives and is a leading cause of disability worldwide.

The study published in this month's Nature Medicine found that coupling between two dopamine receptors was significantly elevated in the brains of people who had been diagnosed with major depression. "We identified a potential therapeutic target for development of novel anti-depressants." said Dr. Fang Liu, Principal Investigator and Senior Scientist in CAMH's Neuroscience Program and Associate Professor of Psychiatry at the University of Toronto. Working from this discovery, researchers sought to find a way to disrupt coupling between the two receptors in hopes that it would have an anti-depressant effect.

Using an autopsied brain study, Dr. Liu and her team initially found that coupling between two dopamine receptors was significantly elevated in the brains of people who had been diagnosed with major depression. They started by analyzing a specific dopamine signaling mechanism, the D1 and D2 receptor complex, to identify the sites where the two receptors bind together. With this information, they were able to generate a protein peptide to disrupt the binding of the two receptors. The peptide was then tested in animal models to compare the effects with existing anti-depressant medications.

"After we administered the peptide, we saw a marked improvement in depression-related behaviors. The improvement seen in the peptide group was equivalent to the improvement on traditional anti-depressant medication".

This peptide is an entirely new approach to treating depression, which has previously relied on medications that primarily block serotonin or norepinephrine transporters. These conventional antidepressant medications don't work for all patients, and can cause various side effects. "We are hopeful that our research will lead to new options for treatment that might have reduced side effects for patients with depression," Dr Liu stated.


'/>"/>

Contact: Michael Torres
media@camh.net
416-595-6015
Centre for Addiction and Mental Health
Source:Eurekalert

Related medicine news :

1. Elseviers BrainNavigator 3.0 reflects the next step in enhancing neurological research
2. NYU researchers identify new neurological deficit behind lazy eye
3. Scientists explain the neurological process for the recognition of letters and numbers
4. Team led by LA BioMed scientist develops novel approach to study neurological disorders
5. University Hospitals Neurological Institute earns Neuroscience Center of Excellence designation
6. University Hospitals Neurological Institute hosts international epilepsy colloquium
7. Rare disease in Amish children sheds light on common neurological disorders
8. Nationally Known Interventional Neuroradiologist John Pile-Spellman, M.D., Joins Neurological Surgery, P.C.
9. Brain Science Institute announces license agreement to develop treatments for neurological disease
10. More Protein, Fewer Refined Carbs May Keep Weight Off
11. Protein found to predict brain injury in children on ECMO life support
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/19/2017)... ... May 19, 2017 , ... The Hill Agencies, a family managed ... throughout the California Central Valley, is announcing a joint charity initiative with the Boys ... a local kid’s camp event. , The Boys and Girls Club of Kern County ...
(Date:5/19/2017)... ... May 19, 2017 , ... The Arnold and Mabel Beckman ... Victor Acosta, Ph.D. - University of New Mexico, Jeremy Baskin, Ph.D. - Cornell ... Washington, Erik Grumstrup, Ph.D. - Montana Stata University, A. Fatih Sarioglu, Ph.D. - ...
(Date:5/19/2017)... ... May 19, 2017 , ... As a groundbreaking surgeon ... the importance of prostate cancer screenings. Early detection of the disease, he says, can ... surgery at Georgia Urology , stands alongside the Georgia Comprehensive Cancer Control’s (GC3) ...
(Date:5/19/2017)... (PRWEB) , ... May 18, 2017 , ... CloSYS products ... for being non-irritating while extremely helpful for mouth and gum health, which is linked ... their professionals and customers learned quickly of the powerful ways in which CloSYS products ...
(Date:5/19/2017)... Santa Clara, CA (PRWEB) , ... May 18, 2017 , ... ... feature that allows sleep labs and physicians to independently dispense CPAP devices and supplies, ... DME orders, and sleep labs can dispense the devices. Device registration for daily usage ...
Breaking Medicine News(10 mins):
(Date:5/10/2017)... BURNIE, Md. , May 10, 2017 ... retention solutions for the clinical research industry, is proud ... www.CSSiEnroll.com . The new website features both enriched ... overall user experience and enhances the company,s already well-established ... the industry. "After many months of ...
(Date:5/9/2017)... , May 9, 2017  Demonstrating its commitment ... of directors for the Pharmaceutical Research and Manufacturers ... membership. Biopharmaceutical companies will now have to meet ... to be eligible to join PhRMA. ... board is sending a clear message that being ...
(Date:5/9/2017)... , May 9, 2017  Semler Scientific, ... provides technology solutions to improve the clinical effectiveness ... results for the first quarter ended March 31, ... products enable our customers to identify when preventive ... intervene before events like heart attacks or strokes ...
Breaking Medicine Technology: